Results 1 to 10 of about 116,064 (169)

Case Report: Novel findings of larotrectinib in children with NTRK-rearranged spindle cell tumor [PDF]

Frontiers in Oncology
Neurotrophic tropomyosin receptor kinase (NTRK)-rearranged spindle cell tumors are often resistant to chemotherapy and radiotherapy. Fortunately, they are sensitive to targeted therapy of tropomyosin receptor kinase (TRK) inhibitors. However, the data on
Linnan Wu, Linnan Wu, Weiji Xie, Weiji Xie, Juan Wang, Juan Wang, Suying Lu, Suying Lu, Yizhuo Zhang, Yizhuo Zhang, Junting Huang, Junting Huang   +11 more
doaj   +2 more sources

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers [PDF]

Journal of Hematology & Oncology, 2018
Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell ...
Yu Chen, Ping Chi
doaj   +3 more sources

Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody [PDF]

Journal of Cancer Research and Clinical Oncology
Purpose Tumor imaging or therapy using cancer specific carriers combined with a radioisotope has huge potential. In radiopharmaceutical development, it is important to ensure target specificity and minimal binding to normal tissues for both tumor ...
Yuki Majima, David Kryza, Mitsuaki Sanada, Jacqueline Sidi-Boumedine, Patrick Mehlen, Benjamin Gibert, Jean-Yves Blay, Fumiyoshi Okano   +7 more
doaj   +2 more sources

Molecular determinants of signal transduction in tropomyosin receptor kinases [PDF]

FEBS Open Bio
Tropomyosin receptor kinase (Trk) receptors are essential regulators of neuronal development, survival, and plasticity through their interactions with neurotrophins.
Giray Enkavi
doaj   +2 more sources

Unraveling the molecular mechanism of novel leukemia mutations on NTRK2 (A203T & R458G) and NTRK3 (E176D & L449F) genes using molecular dynamics simulations approach [version 1; peer review: 2 approved, 1 approved with reservations]

F1000Research, 2023
Background: NTRK1, NTRK2, and NTRK3 are members of the neurotrophic receptor tyrosine kinases (NTRK) family, which encode TrkA, TrkB, and TrkC receptors, respectively.
Fazil Ahmad, Khaldoon Alsamman, Abeer M Al-Subaie, Balu Kamaraj   +3 more
doaj   +1 more source

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

Pharmaceuticals, 2021
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
doaj   +1 more source

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

Molecules, 2022
The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients ...
Jie Wang, Yang Zhou, Xia Tang, Xiuwen Yu, Yongjin Wang, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Zhimin Zhang, Xiaoyun Lu, Zhang Zhang, Ke Ding   +11 more
doaj   +1 more source

Muscle Progenitors Derived from Extraocular Muscles Express Higher Levels of Neurotrophins and their Receptors than other Cranial and Limb Muscles

Cells, 2020
Extraocular muscles (EOMs) show resistance to muscle dystrophies and sarcopenia. It has been recently demonstrated that they are endowed with different types of myogenic cells, all of which present an outstanding regenerative potential. Neurotrophins are
Génova Carrero-Rojas, Beatriz Benítez-Temiño, Angel M. Pastor, Mª América Davis López de Carrizosa   +3 more
doaj   +1 more source

Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer [PDF]

Molecular Cancer Therapeutics, 2018
Abstract Members of the tropomyosin receptor kinase (TRK) family are expressed in their constitutively activated forms as a result of a gene fusion that occurs across a wide variety of cancer types. We have identified CH7057288 as a potent and selective TRK inhibitor that belongs to a novel chemical class.
Hiroshi, Tanaka, Hitoshi, Sase, Toshiyuki, Tsukaguchi, Masami, Hasegawa, Hiromi, Tanimura, Miyuki, Yoshida, Kiyoaki, Sakata, Toshihiko, Fujii, Yukako, Tachibana, Kenji, Takanashi, Atsuko, Higashida, Kiyoshi, Hasegawa, Yoshiyuki, Ono, Nobuhiro, Oikawa, Toshiyuki, Mio   +14 more
openaire   +2 more sources

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort

Diagnostics, 2022
Gene fusions involving NTRK1, NTRK2, and NTRK3 are rare drivers of cancer that can be targeted with histology-agnostic inhibitors. This study aimed to determine the nationwide landscape of NTRK/TRK testing in the Netherlands and the usage of pan-TRK ...
Bart Koopman, Chantal C. H. J. Kuijpers, Harry J. M. Groen, Wim Timens, Ed Schuuring, Stefan M. Willems, Léon C. van Kempen   +6 more
doaj   +1 more source